Pharma Blog Watch

NeoPharm Drug Misses Goal (QDIS Blog)
In his blog, Ed Vawter discusses a recent announcement by NeoPharm that its brain tumor drug, cintredekin besudotox, failed to achieve statistical significance in a Phase III trial. "I should mention that trying to develop treatments for brain tumors, in this case glioblastoma multiforme, is quite difficult. The primary difficulty is in getting drugs to cross the blood-brain barrier."

"Neopharm will be an interesting company to keep in eye on for the next few years to see if their other projects proceed," he writes. "They may become a takeover target if their stock price continues to drop and some company feels there neolipid drug delivery technology is worthwhile. It is estimated that this technology may be worth [approximately] $20 million."